- RAP-219 showed 3.1-point improvement over placebo on 60-point mania scale
- Improvement was 42% from baseline
RAP-219 beat placebo by 3.1 points on a 60-point mania scale, below the 4-point target but a 42% improvement from baseline. Stock surged 20% premarket then closed up 2.7%.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.